Citius Oncology (CTOR) Competitors $1.47 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.45 -0.02 (-1.36%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock CTOR vs. AQST, SNDL, CYRX, IVA, CMPX, ARCT, ACB, ATXS, AURA, and TERNShould you be buying Citius Oncology stock or one of its competitors? The main competitors of Citius Oncology include Aquestive Therapeutics (AQST), SNDL (SNDL), Cryoport (CYRX), Inventiva (IVA), Compass Therapeutics (CMPX), Arcturus Therapeutics (ARCT), Aurora Cannabis (ACB), Astria Therapeutics (ATXS), Aura Biosciences (AURA), and Terns Pharmaceuticals (TERN). These companies are all part of the "pharmaceutical products" industry. Citius Oncology vs. Its Competitors Aquestive Therapeutics SNDL Cryoport Inventiva Compass Therapeutics Arcturus Therapeutics Aurora Cannabis Astria Therapeutics Aura Biosciences Terns Pharmaceuticals Aquestive Therapeutics (NASDAQ:AQST) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, community ranking, earnings, profitability, dividends, media sentiment and analyst recommendations. Does the MarketBeat Community favor AQST or CTOR? Aquestive Therapeutics received 217 more outperform votes than Citius Oncology when rated by MarketBeat users. Likewise, 68.55% of users gave Aquestive Therapeutics an outperform vote while only 33.33% of users gave Citius Oncology an outperform vote. CompanyUnderperformOutperformAquestive TherapeuticsOutperform Votes21868.55% Underperform Votes10031.45% Citius OncologyOutperform Votes133.33% Underperform Votes266.67% Do analysts prefer AQST or CTOR? Aquestive Therapeutics currently has a consensus target price of $10.14, indicating a potential upside of 196.57%. Citius Oncology has a consensus target price of $3.00, indicating a potential upside of 104.08%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Aquestive Therapeutics is more favorable than Citius Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aquestive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Citius Oncology 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders and institutionals hold more shares of AQST or CTOR? 32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 70.5% of Citius Oncology shares are owned by institutional investors. 8.4% of Aquestive Therapeutics shares are owned by insiders. Comparatively, 4.6% of Citius Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better valuation & earnings, AQST or CTOR? Aquestive Therapeutics has higher revenue and earnings than Citius Oncology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAquestive Therapeutics$54.23M6.26-$7.87M-$0.59-5.80Citius OncologyN/AN/A-$21.15MN/AN/A Is AQST or CTOR more profitable? Citius Oncology has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -59.75%. Aquestive Therapeutics' return on equity of 0.00% beat Citius Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Aquestive Therapeutics-59.75% N/A -33.96% Citius Oncology N/A -43.67%-9.74% Does the media favor AQST or CTOR? In the previous week, Aquestive Therapeutics had 5 more articles in the media than Citius Oncology. MarketBeat recorded 7 mentions for Aquestive Therapeutics and 2 mentions for Citius Oncology. Aquestive Therapeutics' average media sentiment score of 1.51 beat Citius Oncology's score of 0.82 indicating that Aquestive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Citius Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, AQST or CTOR? Aquestive Therapeutics has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500. Comparatively, Citius Oncology has a beta of -0.07, suggesting that its stock price is 107% less volatile than the S&P 500. SummaryAquestive Therapeutics beats Citius Oncology on 12 of the 15 factors compared between the two stocks. Get Citius Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CTOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTOR vs. The Competition Export to ExcelMetricCitius OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.18M$6.85B$5.56B$8.50BDividend YieldN/A2.53%5.28%4.16%P/E RatioN/A8.4326.6419.64Price / SalesN/A262.52407.99152.17Price / CashN/A65.8538.2534.64Price / Book-6.686.536.974.60Net Income-$21.15M$143.25M$3.23B$248.06M7 Day Performance39.99%0.21%-0.98%-1.03%1 Month Performance60.45%10.92%7.70%3.50%1 Year PerformanceN/A2.44%31.32%12.68% Citius Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTORCitius OncologyN/A$1.47flat$3.00+104.1%N/A$105.18MN/A0.00N/AGap UpAQSTAquestive Therapeutics1.7188 of 5 stars$3.54-0.6%$10.14+186.5%+17.8%$351.62M$54.23M-7.87160Positive NewsAnalyst RevisionSNDLSNDL3.5805 of 5 stars$1.33+0.8%$3.63+172.6%-34.1%$349.49M$927.61M-4.29580Positive NewsCYRXCryoport3.4471 of 5 stars$6.96-0.6%$11.00+58.0%-34.8%$348.95M$232.13M-2.061,020Trending NewsInsider TradeIVAInventiva2.0752 of 5 stars$3.63+0.4%$10.40+186.9%+5.3%$346.78M$9.20M0.00100Positive NewsGap UpCMPXCompass Therapeutics3.4577 of 5 stars$2.57+2.8%$13.13+410.7%+100.8%$345.71M$850K-6.9520ARCTArcturus Therapeutics3.2121 of 5 stars$12.54-2.0%$53.50+326.6%-59.3%$340.10M$131.27M-5.65180Positive NewsAnalyst RevisionGap DownACBAurora Cannabis0.2996 of 5 stars$5.82+1.7%N/A+0.7%$327.17M$320.81M116.421,340Upcoming EarningsATXSAstria Therapeutics2.3517 of 5 stars$5.79-3.3%$30.00+418.1%-39.7%$326.75MN/A-2.7730News CoveragePositive NewsAnalyst ForecastAnalyst RevisionGap DownAURAAura Biosciences2.6587 of 5 stars$6.29-3.2%$22.00+249.8%-7.9%$326.75MN/A-3.6450Positive NewsGap DownTERNTerns Pharmaceuticals4.125 of 5 stars$3.71+0.3%$15.63+321.2%-46.8%$324.02MN/A-3.1440Positive NewsGap Down Related Companies and Tools Related Companies Aquestive Therapeutics Competitors SNDL Competitors Cryoport Competitors Inventiva Competitors Compass Therapeutics Competitors Arcturus Therapeutics Competitors Aurora Cannabis Competitors Astria Therapeutics Competitors Aura Biosciences Competitors Terns Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTOR) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
